Assessment of UPL’s approach to addressing biodiversity loss
UPL: Overview

UPL Limited is an agricultural and industrial chemicals company based in Mumbai, India. The company mostly produces and sells post-patent (generic) pesticide products.

<table>
<thead>
<tr>
<th>Market cap</th>
<th>₹470.23 billion ($5.71 billion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022 pesticide sales</td>
<td>₹36,300 crore ($4.38 billion)</td>
</tr>
</tbody>
</table>

**Highly Hazardous Pesticides**

≥115

**Top-selling Highly Hazardous Pesticides in 2018**

No data

**EU-banned pesticides notified for export in 2018**

10,131 tonnes (via Arysta LifeScience)

---

UPL produces and sells the highest number of HHPs of all companies assessed. However, it does not appear to have any strategy, targets or methodologies focused on assessing or acting on biodiversity loss from its pesticide products, nor does the company have any established frameworks that guide sustainable solutions development. While UPL is small compared to other assessed companies, it is the largest pesticide producer in India.

---

1 The total volume sold is likely to be lower than that of other assessed companies, as UPL has the lowest annual pesticides sales of all companies.
**INDICATORS OF PROGRESS**

• None

**AREAS OF CONCERN**

• **Product portfolio**: UPL produces and sells the highest number of HHPs of all assessed companies.

• **Biodiversity strategy**: UPL does not disclose a strategy to address pesticide-related biodiversity loss, nor does it have commitments or targets relevant to biodiversity.

• **Impact assessment**: UPL does not disclose a methodology to assess the biodiversity-related impacts or risks posed by its pesticide products.

**Assessment**

1. **Product portfolio**

1.1 **Expectation**: The company does not produce any products with active ingredients that appear in Pesticide Action Network’s list of Highly Hazardous Pesticides.

**ASSESSMENT NOT ACHIEVED**

UPL produces or sells at least 115 active ingredients that are HHPs.

1.2 **Expectation**: If the company is incorporated in a country subject to European Union pesticide use restrictions, it does not sell pesticides that are banned for use in the EU to other countries.

**ASSESSMENT NOT ASSESSED.**

_UPL is not incorporated in a country subject to European Union pesticide use restrictions. However, the company’s subsidiary Arysta LifeScience manufactures chemicals in the EU and is therefore subject to EU regulations on notifying the export of chemicals banned for use in the territory. In 2018, Arysta notified for export 10,131 tonnes of pesticides banned for use in the EU to other countries._
2. Impact assessment

2.1 Expectation: The company assesses its pesticide-related impacts and dependencies on biodiversity, and the risks arising from these, across its full value chain, including downstream impacts.

**ASSESSMENT NOT ACHIEVED**

UPL states that the company “works with experts to assess the impact of its operations on biodiversity as a part of its environmental impact assessment process and takes steps to reduce any negative effects”\textsuperscript{iv}. However, it does not specify if this includes the assessment of pesticide-related impacts throughout the company’s value chain. It does not disclose details about this process or its outcomes\textsuperscript{2}.

The company does not indicate that it assesses pesticide-related risks or dependencies\textsuperscript{2}.

2.2a Expectation: The company uses a clearly defined methodology to assess its impact on biodiversity from all pesticide products, which includes considering how inherent risks of a product materialise throughout the company’s value chain and impact biodiversity at the location-level.

**ASSESSMENT NOT ACHIEVED**

UPL does not disclose a methodology it uses to assess the biodiversity impact of its pesticide products.

2.2b Expectation: The company’s methodology for impact assessment was developed in partnership with, and peer reviewed by, independent subject-matter experts, as evidenced by a disclosure of all relevant details of the company’s relationship and the nature of collaboration with all experts involved.

**ASSESSMENT NOT ACHIEVED**

UPL does not disclose a methodology it uses to assess the biodiversity impact of its pesticide products.

\textsuperscript{2}The company has stated in conversations with ShareAction that it is in the process of conducting life cycle assessments, but these do not include biodiversity.
3. Biodiversity strategy

3.1 Expectation: In alignment with the Global Biodiversity Framework’s Target 7, the company has commitments and targets that seek to reduce the company’s impact on or risk to biodiversity from its pesticide products by 50 per cent by 2030.

**ASSESSMENT NOT ACHIEVED**

UPL’s commitments and targets do not align with GBF Target 7.

UPL has committed to “achieve Net Positive Impact on biodiversity across our company’s value chain by 2030”\(^v\). The company has not specified how this will be achieved or how progress will be measured.

3.2 Expectation: The company has committed to phase out production of Highly Hazardous Pesticides by 2035.

**ASSESSMENT NOT ACHIEVED**

UPL has not publicly committed to phase out production of HHPs.

3.3 Expectation: The company has a management plan for locations within its downstream value chain that are at medium or high risk of negative biodiversity impacts from pesticide use, including areas of biodiversity importance. This plan includes restricting sales of some products to at-risk locations.

**ASSESSMENT NOT ACHIEVED**

UPL has not disclosed a management plan to protect locations in its value chain at medium or high risk of biodiversity loss from pesticide use.

3.4 Expectation: The company has a clear biodiversity strategy, which sets out how it will meet biodiversity-related commitments and targets.

**ASSESSMENT NOT ACHIEVED**

UPL has not disclosed a strategy to address biodiversity loss. The company has a Biodiversity Policy; however, this does not reference the impact on biodiversity of the company’s pesticide products. It focuses primarily on environmental stewardship around production facilities that it owns and operates\(^vi\).
4. Disclosures

4.1 Expectation: The company’s biodiversity disclosures fully align with standards set by the Global Reporting Initiative 304 guidance on biodiversity. The company has committed to implement the disclosure framework set by the Taskforce for Nature-related Financial Disclosures and to report biodiversity-related impacts, dependencies and risks in alignment with Global Biodiversity Framework Target 15.

ASSESSMENT NOT ACHIEVED

UPL states that it reports against some topic areas required by GRI 304. However, the company does not report against all topics, nor does it provide all details required by the topics it does report against, to be considered fully aligned with this standard.

UPL has not committed to align with or report against the TNFD framework or GBF Target 15.

4.2 Expectation: The company publishes an exhaustive list of active ingredients included in its products and discloses annual sales volumes of Highly Hazardous Pesticides.

ASSESSMENT NOT ACHIEVED

UPL does not disclose this information.

4.3 Expectation: The company discloses locations where its pesticide products are used that have been identified as at-risk, including those at medium or high risk of negative biodiversity impacts from pesticide use and those in or near areas of biodiversity importance.

ASSESSMENT NOT ACHIEVED

UPL does not disclose this information.

4.4 Expectation: The company discloses toxicological studies of all active ingredients included in its product portfolio, including all studies submitted to regulators for product approval.

ASSESSMENT NOT ACHIEVED

UPL does not disclose any studies of its active ingredients.
5. Product innovation

5.1 Expectation: The company assesses the inherent risks of proposed agricultural solutions or those in development and ensures all new solutions pose the lowest possible risks to biodiversity.

**ASSESSMENT** NOT ACHIEVED

UPL does not indicate that it assesses the biodiversity risks of proposed alternative solutions or ensures that they pose the lowest possible risks to biodiversity.

5.2 Expectation: The company has a target (such as sales, portion of product portfolio, or research and development spending) for expanding safer and sustainable alternatives.

**ASSESSMENT** NOT ACHIEVED

UPL has not published any targets for expanding safer and sustainable alternatives.

5.3 Expectation: The company’s innovation practices explicitly include replacing hazardous products with lower risk alternatives.

**ASSESSMENT** NOT ACHIEVED

UPL does not appear to have a methodology, criteria or policy around sustainable innovation that includes this principle.
UPL (2023) Reimagining Sustainability Expanding value horizons. Available at: https://www.upl-ltd.com/financial_result_and_report_pdfs/AZtfl7Zh3Y21abzy9TOzPqH2Z0R0R3GwSAGJa2mM/UPL-ANNUAL-REPORT-_FY-2023.pdf (Page 42)

In addition to producing generic-brand pesticides, the company also appears to sell pesticides developed by other companies. This number includes HHPS that UPL sells, such as BASF’s Opera™ (marketed here by UPL) which includes the HHP epoxiconazole. It also includes HHPS sold by the company’s subsidiary, Arysta LifeScience.

Dataset available for download at: https://www.publiceye.ch/en/topics/pesticides/banned-in-europe

UPL (2023) Biodiversity: UPL’s Top to Bottom Driven Management Approach. Available at: https://www.upl-ltd.com/sustainability/biodiversity

UPL (2023) UPL Biodiversity Policy. Available at: https://www.upl-ltd.com/pdf/biodiversity/Biodiversity-Policy.pdf

UPL (2023) UPL Biodiversity Policy.
Disclaimer

ShareAction does not provide investment advice. The information herein is not intended to provide and does not constitute financial or investment advice. ShareAction makes no representation regarding the advisability or suitability of investing or not in any particular financial product, shares, securities, company, investment fund, pension or other vehicle, or of using the services of any particular organisation, consultant, asset manager, broker or other provider of investment services. A decision to invest or not, or to use the services of any such provider should not be made in reliance on any of the statements made here. You should seek independent and regulated advice on whether the decision to do so is appropriate for you and the potential consequences thereof. While every effort has been made to ensure that the information is correct, ShareAction, its employees and agents cannot guarantee its accuracy and shall not be liable for any claims or losses of any nature in connection with information contained in this document, including (but not limited to) lost profits or punitive or consequential damages or claims in negligence.

Fairshare Educational Foundation (t/a ShareAction) is a company limited by guarantee registered in England and Wales number 05013662 (registered address 63/66 Hatton Garden, Fifth Floor, Suite 23, London UK, EC1N 8LE) and a registered charity number 1117244, VAT registration number GB 211 1469 53.

About ShareAction

ShareAction is a NGO working globally to define the highest standards for responsible investment and drive change until these standards are adopted worldwide. We mobilise investors to take action to improve labour standards, tackle climate change and address pressing global health issues. Over 15 years, ShareAction has used its powerful toolkit of research, corporate campaigns, policy advocacy and public mobilisation to drive responsibility into the heart of mainstream investment. Our vision is a world where the financial system serves our planet and its people.

Visit shareaction.org or follow us @ShareAction to find out more.

Authors

Eve Gleeson